In August 2021, the center obtained institutional certification as a drug clinical trial site from the regulatory authority. It has established a research alliance covering 11 departments across five Grade A tertiary hospitals, with five ongoing clinical projects. Key projects include autologous tumor-infiltrating lymphocyte injection for advanced solid tumors and research on immune-related adverse events in tumor immunotherapy, all of which have yielded promising clinical data.
(Beijing) Medical Advertising [2026] No. 05-10-1229 Beijing ICP Registration No. 09100222-1 Legal Notice and Privacy Policy
Amcare Healthcare Group
